Allo-HCT with post-transplant cyclophosphamide in older adults: similar safety and a viable option compared to younger adults
Despite higher relapse rates leading to lower OS in older adults, similar NRM and comparable early toxicities support the feasibility of allo-HCT with PTCy in patients ≥65 years.
Authors
- Jordi Esteve
- Gorka Iza Pinedo
- Mrs. María Queralt Salas
- Maria Suárez-Lledó
- Joan Gisbert Cid
- Paola Charry (ORCID: https://orcid.org/0000-0002-4777-9643)
- Francesc Fernández‐Avilés (ORCID: https://orcid.org/0000-0002-3733-590X)
- Carlos Martínez (ORCID: https://orcid.org/0000-0003-3307-1326)
- Montserrat Rovira
- Laia Guardia
- Enric Carreras
- Miquel Lozano
- Maite Antonio
- Alejandra Pedraza
- Berta Solé
Institutions
- Canary Institute of Cancer Research (ES)
- Institut Català d'Oncologia (ES)
- Hospital de Cruces (ES)
- Fundación Josep Carreras Contra la Leucemia (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-07
- DOI
- https://doi.org/10.3389/fimmu.2025.1678899
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00